Breast cancer heterogeneity: Need to review current treatment strategies

Current Breast Cancer Reports

Volumn 4, Issue 4, 2012, Pages 225-231

  Malik, Fayaz ^a   Korkaya, Hasan ^a   Clouthier, Shawn G ^a   Wicha, Max S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Breast cancer; Breast cancer subtypes; Cancer stem cells; Circulating tumor cells; Drug resistance; HER2; Luminal; Metastasis; Trastazumab; Tumor heterogeneity

Indexed keywords

BCR ABL PROTEIN; CD24 ANTIGEN; CHEMOKINE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLEEVIC; HERMES ANTIGEN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LAPATINIB; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B BETA; STAT3 PROTEIN; TRANSCRIPTION FACTOR TWIST; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE METASTASIS; BRCA GENE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RESISTANCE; CANCER RISK; CANCER STEM CELL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CELL CLONE; CELL CULTURE; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL FUNCTION; CELL HETEROGENEITY; CELL INTERACTION; CELL INVASION; CELL LINEAGE; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL SUBPOPULATION; CELLULAR STRESS RESPONSE; CHROMATIN; CHRONIC MYELOID LEUKEMIA; CIRCULATING TUMOR CELL; COPY NUMBER VARIATION; CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION; DRUG EFFICACY; EARLY DIAGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EXPERIMENTAL MOUSE; FEEDBACK SYSTEM; GENE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL; HUMAN; INTRACELLULAR SIGNALING; MALIGNANT TRANSFORMATION; METASTASIS; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE NEU; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; P53 GENE; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STROMA CELL; TARGET CELL; THERAPY EFFECT; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR XENOGRAFT;

EID: 84872197199     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-012-0093-5     Document Type: Article

References (74)

1. Siegel RD, Naishadham AJ. Cancer statistics. 2012. CA Cancer J Clin. 2012;62:10-29.
2. Stephens PJ, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486:400-4. A recent study which showed that breast cancer is genetically much more diverse than was thought. Genetic analysis of thousands of genes revealed the presence of 9 new cancer genes and 70 combinations of driver mutations that can cause the development of breast cancer..
3. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
4. Neve RM, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515-27. (Pubitemid 44854747)
5. Kao J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 2009;4(7):e6146.
6. •• Curtis C, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature. 2012;486:346-52. In this large study, genetic analysis of 2000 frozen samples of breast cancer tumors, taken from women diagnosed with the disease over the past 10 years was done. Study showed that breast cancer is highly heterogenic disease and reclassified it in 10 different subtypes according to their genetic analysis..
7. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23-8.
8. Lindeman GJ, Visvader JE. Insights into the cell of origin in breast cancer and breast cancer stem cells. Asia Pac J Clin Oncol. 2010;6 (2):89-97.
9. Shipitsin M, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259-73. (Pubitemid 46349843)
10. •• Gerlinger M, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-92. This article describes tumor heterogeneity during multiregion sequencing of primary tumors in patients. The findings from this study suggest that gene profiling from a single tumor biopsy may not be able to show the overall picture of the tumor and is not ideal for biomarker studies or treatment development..
11. Bertos NR, Park M. Breast cancer - one term, many entities? J Clin Invest. 2011;121(10):3789-96.
12. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle. 2007;6:2332-8. (Pubitemid 350058682)
13. Polyak K, et al. Breast tumor heterogeneity: causes and consequences. Breast Cancer Res. 2009;11 Suppl 1:S18.
14. Baylin SB, Jones PA. A decade of exploring the cancer epigenome- biological and translational implications. Nat Rev Cancer. 2011;11:726-34.
15. Hunter DJ, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39:870-4. (Pubitemid 47014500)
16. Long J, et al. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet. 2012;8:e1002532.
17. Easton DF, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087-93. (Pubitemid 47014426)
18. Calabrese P, Tavare S, Shibata D. Pretumor progression: clonal evolution of human stem cell populations. Am J Pathol. 2004;164:1337-46. (Pubitemid 38387799)
19. Foulkes WD, Reis-Filho JS, Narod SA. Tumor size and survival in breast cancer-A reappraisal. Nat Rev Clin Oncol. 2010;7:348-53.
20. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-A paradigm shift. Cancer Res. 2006;66:1883-90. discussion 1895-6.
21. Morris RJ. A perspective on keratinocyte stem cells as targets for skin carcinogenesis. Differentiation. 2004;72:381-6. (Pubitemid 41702115)
22. Tokunaga M, et al. Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950-74. J Natl Cancer Inst. 1979;62:1347-59. (Pubitemid 9194997)
23. Cobaleda C, et al. The emerging picture of human breast cancer as a stem cell-based disease. Stem Cell Rev. 2008;4:67-79.
24. Welch JS, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264-78.
25. Dingli D, Pacheco JM. Stochastic dynamics and the evolution of mutations in stem cells. BMC Biol. 2011;9:41.
26. Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-7. (Pubitemid 32267972)
27. Graham SM, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319-25.
28. Corbin AS, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396-409. The authors showed that BCRABL kinase is active in CML stem cells, in spite of inhibiting Tyrosine kinase activity; there is no effect on CML stem cells as these cells switch their dependence on cytokines for survival and proliferation. These results demonstrate that a different therapeutic approach is needed to address non-responsive CML stem cells..
29. Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:671-84. x. (Pubitemid 38969138)
30. Anderson K, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469:356-61.
31. Liu S, Clouthier SG, Wicha MS. Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia. 2012;17:15-21.
32. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012;13:e178-85.
33. Nass SJ, et al. Aberrant methylation of the estrogen receptor and Ecadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res. 2000;60:4346-8. (Pubitemid 32103608)
34. Hu M, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet. 2005;37:899-905. (Pubitemid 41077119)
35. Park SY, et al. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes. Mod Pathol. 2012;25:185-96.
36. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012;21:283-96.
37. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805:105-17.
38. Allinen M, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17-32. (Pubitemid 38903159)
39. Ma XJ, et al. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11:R7.
40. Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res. 2011;17:6125-9.
41. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139:693-706.
42. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-74. (Pubitemid 32878711)
43. Al-Ejeh F, et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis. 2011;32:650-8.
44. Al-Hajj M, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-8. (Pubitemid 36418143)
45. Mauri D, et al. Survival with aromatase inhibitors and inactivators vs standard hormonal therapy in advanced breast cancer: metaanalysis. J Natl Cancer Inst. 2006;98:1285-91. (Pubitemid 44530724)
46. Wolff AC, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43. (Pubitemid 46174133)
47. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92. This study revealed the benefits of trastazumab treatment along with the conventional chemotherapies during phase 3 clinical trial. The results of this study showed that patients with metastatic breast cancer overexpressing HER2, when given a concurrent treatment of trastuzumab along with first-line chemotherapy, can significantly regulate the disease progression and improve overall survival.. 48. Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-67. (Pubitemid 32222155)
48. Hennessy BT, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69:4116-24.
49. Arslan C, et al. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets. 2011;15:21-30.
50. Ding L, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464:999-1005.
51. Aktas B, et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11: R46. In this study blood samples from metastatic breast cancer patients were studied for the presence of CTCs and therapeutic response. It was found that a major proportion of CTCs of metastatic breast cancer patients exhibit EMT and tumor stem cell characteristics.
52. Piccart-Gebhart MJ, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-72. (Pubitemid 41464705)
53. Vogel CL, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-26. (Pubitemid 34111379)
54. Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84. (Pubitemid 41464706)
55. Press MF, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095-105. (Pubitemid 34791099)
56. •• Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358:1409-11. This ground breaking (NSABP, B-31) breast cancer trial, suggests that the benefit of adjuvant trastuzumab may not be limited to patients based on the HER2 gene amplification. Studies showed that patients with non-Amplified HER2 gene have a significant response to HER2 targeted therapy in the adjuvant setting.. (Pubitemid 351468442)
57. Tuma RS. Inconsistency of HER2 test raises questions. J Natl Cancer Inst. 2007;99:1064-5.
58. Lipton A, et al. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer. 2010;116:5168-78.
59. •• Korkaya H, et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27:6120-30. This study showed the role of HER2 in expanding the stem/progenitor cell population and how it leads to increase in the tumorigenicity and invasiveness of breast cancer..
60. Korkaya H, Wicha MS. HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res. 2009;15:1845-7.
61. Magnifico A, et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res. 2009;15:2010-21.
62. Vincent-Salomon A, et al. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer. 2007;96:654-9.
63. Fehm T, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007;9:R74.
64. Wulfing P, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006;12:1715-20.
65. Braun S, et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res. 2001;61:1890-5. (Pubitemid 32692004)
66. •• Georgoulias V, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol. 2012. This phase 2 clinical study showed the benefits of adjuvant trastazumab treatment in the patients. The efficacy of trastazumab was due to its targeting of chemoresistant CTCs leading to significantly reduced risk of relapse and prolonged disease-free survival in comparison to the patients who only received standard treatment.
67. Hayes DF, et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol. 2002;21:1111-7.
68. Shafee N, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008;68:3243-50.
69. Hambardzumyan D, Squatrito M, Holland EC. Radiation resistance and stem-like cells in brain tumors. Cancer Cell. 2006;10:454-6. (Pubitemid 44854752)
70. Korkaya H, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009;7:e1000121.
71. Diehn M, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780-3.
72. Li X, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672-9.
73. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res. 2000;103:57-75.
74. Houssami N, et al. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-Analysis. Breast Cancer Res Treat. 2011;129:659-74.